4D Molecular Therapeutics (FDMT) Depreciation & Amortization (CF) (2020 - 2026)

4D Molecular Therapeutics (FDMT) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 20.74% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $4.9 million (up 8.41% YoY), while the FY2025 annual figure was $4.7 million, up 0.88% from the prior year.
• Depreciation & Amortization (CF) climbed to $1.3 million in Q1 2026 per FDMT's latest filing, from $1.2 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.3 million in Q1 2026 and bottomed at $406000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.0 million across 5 years, with a median of $1.1 million in 2024.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 160.0% — and 2025, when it decreased 10.4%.
• 4D Molecular Therapeutics' Depreciation & Amortization (CF) stood at $1.0 million in 2022, then grew by 8.68% to $1.1 million in 2023, then decreased by 0.54% to $1.1 million in 2024, then grew by 10.95% to $1.2 million in 2025, then grew by 4.36% to $1.3 million in 2026.
• Business Quant data shows FDMT's Depreciation & Amortization (CF) at $1.3 million in Q1 2026, $1.2 million in Q4 2025, and $1.3 million in Q3 2025.